HEMACARE CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+0.08% | +0.24% |
| Sales 2017 | 20.21M 1.61B | Sales 2018 | 28.51M 2.27B | Capitalization | 125M 9.95B |
|---|---|---|---|---|---|
| Net income 2017 | 4M 319M | Net income 2018 | 4M 319M | EV / Sales 2017 | 1.29 x |
| Net cash position 2017 | 9.06M 723M | Net cash position 2018 | 9.9M 790M | EV / Sales 2018 | 4.03 x |
| P/E ratio 2017 |
8.18
x | P/E ratio 2018 |
27.6
x | Employees | - |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 94.17% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Colin S. Dunn
CEO | Chief Executive Officer | - | - |
David Smith
DFI | Director of Finance/CFO | 58 | - |
Maria Pia Muniz
COO | Chief Operating Officer | - | 31/12/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colin S. Dunn
CEO | Chief Executive Officer | - | - |
Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.24% | 346M | |
| -28.69% | 85.35B | |
| +14.32% | 81.95B | |
| +9.37% | 28.99B | |
| -11.43% | 16.98B | |
| -0.36% | 16.85B | |
| -0.24% | 15.35B | |
| +4.32% | 12.42B | |
| +33.40% | 12.19B | |
| -31.40% | 11.89B |
- Stock Market
- Equities
- HEMA Stock
